Team McCallum

R&D for Lifetime of Life

IBS v Xifaxan (rifaximin).

Dr Mark Pimentel reported on the effectiveness of Xifaxan in treatment of irritable bowel syndrome in phase 3 clinical trials involving 1260 people.

These people received 550mg mg Xifaxan or placebo 3 times a day for 14 days.

Target 1. The percentage who had adequate relief in of IBS symptoms in 2 or more of the 4 weeks after this treatment. Results – placebo 31% – Xifaxan 41%.

Target 2. As above, but replace IBS symptoms with bloating. Results – placebo 32% – Xifaxan 41%.

According to Science Daily, “Rifaximin is marketed by Salix Pharmaceuticals, Inc. Salix also provided funding for the studies. Pimentel discovered the use of rifaximin for IBS, and Cedars-Sinai holds patent rights to this discovery and has licensed rights to the invention to Salix. Dr. Pimentel is a consultant to Salix, Inc, and serves on its scientific advisory board.”


May 8, 2010 - Posted by | IBD, Mark Pimentel

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: